Bolt Biotherapeutics
Bolt Biotherapeutics is developing its novel BoltbodyTM platform, a cancer immunotherapy that consists of Immune-Stimulating Antibody Conjugates (ISAC).
2
Funding Rounds
$147.5m
Money raised
| Name | Phone | Social networks | |
|---|---|---|---|
| Ed*** G. En****** | - | - | - |
| Name | Phone | Social networks | |
|---|---|---|---|
| Ed*** G. En****** | - | - | - |
| Ma****** G. Sh** | - | - | - |
| Ri***** Mi**** | - | - | - |
| Ra***** Sc******* | - | - | |
| Fr*** D. Le* | - | - | - |
Funding series
Funding Series Analysis
The company Bolt Biotherapeutics has raised a total of $93.5m in funding over 2 rounds.
Key Insights:
- Bolt Biotherapeutics, Inc. Series C round, July 2020: $93.5m
- Bolt Biotherapeutics Series B round, February 2019: $54m
Bolt Biotherapeutics, Inc. Series C round, July 2020
$93.5m
Bolt Biotherapeutics Series B round, February 2019
$54m
Industries
Bolt Biotherapeutics is active in the following industries:
- Synthetic chemistry
- Pharmaceutical industry
- Biomedical engineering
- Technology
- Cancer
- Oncology
- Consumer biotechnology
- Biology
- Biotechnology
- Internal medicine
- Healthcare
- Medicine
- Engineering